3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Triple Negative Breast Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Glioblastoma
2
Carcinoma, Non-Small-Cell Lung
2
Thoracic Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Newly Diagnosed Glioblastoma
1
Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Lymphoma, Large B-Cell, Diffuse
1
Locally Advanced or Metastatic Solid Tumors
1
Glioma
1
Carcinoma, Merkel Cell
1
Carcinoma
1
Breast Neoplasms
1
Interventions
Trastuzumab
209
Paclitaxel
187
Fulvestrant
161
Capecitabine
150
Docetaxel
136
Letrozole
127
exemestane
92
palbociclib
76
Anastrozole
75
Cyclophosphamide
71
Lapatinib
69
Gemcitabine
66
Bevacizumab
66
pertuzumab
61
pembrolizumab
60
ribociclib
59
Carboplatin
59
abemaciclib
53
eribulin
48
Doxorubicin
45
Vinorelbine
41
Everolimus
41
Ado-Trastuzumab Emtansine
41
Tamoxifen
40
130-nm albumin-bound paclitaxel
34
Injections
31
trastuzumab deruxtecan
30
Albumin-Bound Paclitaxel
26
olaparib
24
Alpelisib
24
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Breast Neoplasms
×
efineptakin alfa
×
Clear all
NCT03752723
2024-03-05
KEYNOTE-899
Genexine, Inc.
Phase 1/2
Completed
84 enrolled